ADAP Adaptimmune Therapeutics plc

5.05
-0.08  -2%
Previous Close 5.13
Open 5.08
52 Week Low 2.83
52 Week High 13.4
Market Cap $783,446,622
Shares 155,137,945
Float 123,996,133
Enterprise Value $451,351,657
Volume 939,799
Av. Daily Volume 918,475
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
MAGE-A4 (SPEARHEAD‑1)
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
AFP (ADP-A2AFP)
Hepatocellular carcinoma
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
MAGE-A4 (ADP-A2M4CD8 - SURPASS)
Solid tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
MAGE-A4 (ADP-A2M4)
Solid tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
ADP-A2M4CD8
Gastroesophageal cancers
Phase 1
Phase 1
Phase 2 trial to commence 1H 2021.
MAGE-A10 (ADP-A2M10)
Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Phase 1
Phase 1 enrolment completed 2019.

Latest News

  1. - Outlined strategy to build integrated cell therapy company and the Company's "2-2-5-2" five-year core value drivers -

    - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric junction, and melanoma cancers confirming potential of SPEAR T-cells for solid tumors -

    - Completed enrollment of SPEARHEAD-1 clinical trial, to support planned BLA filing and commercialization in 2022 for ADP-A2M4 for people with synovial sarcoma -

    - Initiating Phase 2 trial (SURPASS-2) with ADP-A2M4CD8 in esophageal and esophagogastric junction cancers in 1H 2021 -

    - Demonstrated killing of cancer cells with T-cells derived from the Company's allogeneic platform. MAGE-A4…

    - Outlined strategy to build integrated cell therapy company and the Company's "2-2-5-2" five-year core value drivers -

    - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric junction, and melanoma cancers confirming potential of SPEAR T-cells for solid tumors -

    - Completed enrollment of SPEARHEAD-1 clinical trial, to support planned BLA filing and commercialization in 2022 for ADP-A2M4 for people with synovial sarcoma -

    - Initiating Phase 2 trial (SURPASS-2) with ADP-A2M4CD8 in esophageal and esophagogastric junction cancers in 1H 2021 -

    - Demonstrated killing of cancer cells with T-cells derived from the Company's allogeneic platform. MAGE-A4 and mesothelin to be first allogeneic programs into the clinic -

    - Financial guidance confirmed: funded into early 2023 -

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020, and provided a business update.

    "We are building the cell therapy company of the future for people with cancer. With our ‘2-2-5-2' by 2025 strategic plan, we will deliver value with marketed SPEAR T-cell products starting with ADP-A2M4 for people with synovial sarcoma," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "We completed enrollment in our SPEARHEAD-1 trial in approximately 12 months to support our first BLA, which is strong evidence of our ability to execute rapidly. We are focusing the SURPASS trial, using our next-generation ADP-A2M4CD8 product, on lung, gastroesophageal, head and neck, and bladder cancers to identify new indications to take forward to late-stage development."

    Planned 2021 data updates1

    • SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma
      • June: preliminary data at American Society of Clinical Oncology (ASCO)
      • November: full update at Connective Tissue Oncology Society (CTOS)
    • SURPASS Phase 1 trial with ADP-A2M4CD8 (next-generation product targeting MAGE-A4)
      • September: update at European Society for Medical Oncology (ESMO)
    • Additional clinical updates
      • September: update at International Liver Cancer Association (ILCA) conference for ADP-A2AFP Phase 1 trial for people with liver cancer
      • October: update at American Society for Radiation Oncology (ASTRO) for radiation sub-study of the ADP-A2M4 Phase 1 trial2
      • November: ADP-A2M4 translational data update at Society for Immunotherapy of Cancer (SITC)

    "2-2-5-2" by 2025 strategic plan

    At an Investor Day held in November 2020, the Company outlined its "2-2-5-2" by 2025 strategic plan encompassing:

    "2" - Two marketed products targeting MAGE-A4

    Estimated potential addressable population in tumor types with significant MAGE-A4 expression, factored for HLA-A23, is ~39,000 patients per year in the US and EU

    Durable responses in synovial sarcoma – on track to file a Biologics License Application (BLA) for ADP-A2M4 in 2022

    • The first commercial opportunity for SPEAR T-cells targeting MAGE-A4 will be in synovial sarcoma with plans to file a BLA in the US in 2022
    • In 2020, the Company received positive endorsements from regulatory authorities with Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) in the US, and access to PRIority MEdicines (PRIME) regulatory support and ODD in the EU
    • Data from the Phase 1 trial with ADP-A2M4 (presented at CTOS 2020)
      • In 16 patients with synovial sarcoma, there was an Overall Response Rate of 44% and a Disease Control Rate of 94%
      • Responses were durable with a median duration of response of 28 weeks with ongoing responses beyond 72 weeks in two patients (median overall survival had not been reached)
      • These data are considerably superior4 to response rates observed with available second line therapies in synovial sarcoma

    SURPASS-2 in esophageal and esophagogastric junction (EGJ) cancers in 1H 2021

    • The Company will initiate a Phase 2 trial, SURPASS-2, with ADP-A2M4CD8 (next-generation SPEAR T-cells targeting MAGE-A4 that co-express CD8α intended to increase potency) for patients with esophageal or EGJ cancers in 1H 2021
    • SURPASS-2 is supported by encouraging data from the Phase 1 SURPASS trial (presented at SITC 2020) with one confirmed partial response (PR) in a patient with EGJ cancer and tumor reductions in two additional patients (1 with esophageal and 1 with EGJ cancer)
    • The trial will be conducted at multiple centers in North America and the EU, and is intended to enroll 45 people with esophageal or EGJ cancers to be treated with doses up to 10 billion SPEAR T-cells
    • The Company also presented preclinical data at SITC 2020 indicating that AKT inhibition during the manufacture of SPEAR T-cells results in a more consistent expansion and phenotype of the final product. This process is currently being used for the Phase 1 SURPASS trial.

    "2" - Two additional BLAs for SPEAR T-cell products

    • Adaptimmune's Phase 1 SURPASS trial with ADP-A2M4CD8 continues to enroll patients, focusing on lung, gastroesophageal, head and neck, and bladder cancers – indications for which the Company has reported responses or signs of efficacy with its MAGE-A4 targeted products
    • In 2020, Adaptimmune initiated SPEARHEAD-2 with its first-generation SPEAR T-cells targeting MAGE-A4 in combination with pembrolizumab for people with head and neck cancers
    • The Phase 1 trial with ADP-A2AFP for people with liver cancer is ongoing. As presented at ILC 2020, nine patients were treated as of the data cut-off and best responses were:
      • One patient with a complete response, one with stable disease (SD), and two with progressive disease (PD) among the four patients who received ~5 billion or more SPEAR T-cells
      • Five patients with SD who received doses of 100 million and 1 billion SPEAR T-cells in the first two dose cohorts

    "5" - Five new autologous products in the clinic

    • Adaptimmune has a deep preclinical pipeline from which it expects to bring five new products into the clinic.
    • These include multiple possibilities for next-generation autologous SPEAR T-cells such as:
      • ADP-A2AFP SPEAR T-cells co-expressing CD8α
      • ADP-A2M4 SPEAR T-cells co-expressing IL-7, IL-15, dnTGFβ, and/ or PDE7
      • Enhancing SPEAR T-cells with IL-7 for proliferation and survival and CCL19 for migration into tumor in collaboration with Noile-Immune Biotech, Inc.
      • Enhancing SPEAR T-cells using transmembrane and surface immunoregulatory mechanisms with Alpine Immune Sciences, Inc.
    • The Company is also developing new products, including:
      • Expanding into HLAs beyond HLA-A2 to increase the addressable patient population
      • HLA-independent TCR (HiT) candidates for multiple targets including GPC3
      • A new program for next-generation TILs co-expressing IL-7 in melanoma in collaboration with leading TIL therapy center (CCIT, Denmark)

    "2" - Two allogeneic products in the clinic

    • In January 2020, Adaptimmune announced it had entered into an agreement to co-develop and co-commercialize stem-cell derived allogeneic cell therapies with Astellas
      • The first target nominated is a HiT targeting mesothelin
    • At ASGCT 2020, Adaptimmune presented data with evidence of its allogeneic platform demonstrating differentiation of functional T-cells from human-induced pluripotent stem cells (hiPSCs) that can kill MAGE-A4 expressing target cells in vitro –targeted to become the Company's first allogeneic product in the clinic

    Corporate updates from 2020

    • Despite the impact of the COVID-19 pandemic on the biotechnology industry, Adaptimmune continued to see improved enrollment in its clinical trials
    • In Q1, the Company received an upfront payment of $50 million from Astellas. The Company is also entitled to receive research funding of up to $7.5 million per collaboration target per year
    • Underwritten public offering in Q1 generated net proceeds of approximately $90 million
    • Underwritten public offering in Q2 generated net proceeds of approximately $244 million

    Financial Results for the fourth quarter and year ended December 31, 2020

    • Cash / liquidity position: As of December 31, 2020, Adaptimmune had cash and cash equivalents of $56.9 million and Total Liquidity5 of $368.2 million.



    • Revenue: Revenue for the fourth quarter and year ended December 31, 2020 was $1.5 million and $4.0 million, respectively, compared to $0.7 million and $1.1 million for the same periods in 2019. The increase was due to revenue arising under the collaboration agreement with Astellas, which was entered into in January 2020.



    • Research and development (R&D) expenses: R&D expenses for the fourth quarter and year ended December 31, 2020 were $25.8 million and $91.6 million, respectively, compared to $20.4 million and $97.5 million for the same periods in 2019. R&D expenses in the year ended December 31, 2019 included the accrual of a purchase commitment and higher costs for in-process research and development; excluding the impact of these, research and development expenses have increased as the Company progresses development of its cell therapies.



    • General and administrative (G&A) expenses: G&A expenses for the fourth quarter and year ended December 31, 2020 were $13.2 million and $45.8 million, respectively, compared to $10.7 million and $43.4 million for the same periods in 2019. The increase in G&A expenses was due to an increase in general corporate costs, including professional fees and insurance.



    • Net loss: Net loss attributable to holders of the Company's ordinary shares for the fourth quarter and year ended December 31, 2020 was $36.6 million and $130.1 million ($(0.15 per ordinary share), compared to $29.4 million and $137.2 million ($(0.22) per ordinary share) for the same periods in 2019.

    Financial Guidance

    The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company's current operations into early 2023, as further detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, to be filed with the Securities and Exchange Commission following this earnings release.

    Conference Call Information

    The Company will host a live teleconference and webcast to provide additional details at 8:00 a.m. EST (1:00 p.m. GMT) today, February 25, 2021. The live webcast of the conference call will be available via the Events page of Adaptimmune's corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, if preferred, please dial (833) 652-5917 (US or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (2099860).

    About Adaptimmune

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. 

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

    Total Liquidity (a non-GAAP financial measure)

    Total Liquidity (a non-GAAP financial measure) is the total of cash and cash equivalents and marketable securities (available-for-sale debt securities). Each of these components appears separately in the consolidated balance sheet. The US GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the consolidated financial statements, which reconciles to Total Liquidity as follows (in millions):

           
         December 31,     December 31, 
      2020 2019
    Cash and cash equivalents $56,882 $50,412
    Marketable securities - available-for-sale debt securities  311,335  39,130
    Total Liquidity $ 368,217 $ 89,542

    The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its assessment of overall liquidity, financial flexibility, capital structure and leverage.

    Consolidated Statement of Operations

    (unaudited, in thousands, except per share data)

                    
      Three months ended    Year ended
      December 31,    December 31,
      2020

        2019

        2020

        2019

    Revenue   1,502    728       3,958    1,122 
    Operating expenses               
    Research and development (including losses accrued on firm purchase commitments of $0, $0, $0 and $5,000)  (25,777)  (20,354)     (91,568)  (97,501)
    General and administrative  (13,238)  (10,729)     (45,795)  (43,391)
    Total operating expenses   (39,015)   (31,083)      (137,363)   (140,892)
    Operating loss   (37,513)   (30,355)      (133,405)   (139,770)
    Interest income  538   448      2,313   2,772 
    Other income (expense), net  414   631      1,162   75 
    Loss before income taxes   (36,561)   (29,276)      (129,930)   (136,923)
    Income taxes  (52)  (88)     (162)  (242)
    Net loss attributable to ordinary shareholders $ (36,613) $ (29,364)    $ (130,092) $ (137,165)
                    
    Net loss per ordinary share               
    Basic and diluted $ (0.04) $ (0.05)    $ (0.15) $ (0.22)
                    
    Weighted average shares outstanding:               
    Basic and diluted  928,676,161   630,994,079      854,783,763   629,805,218 

    Consolidated Balance Sheets

    (unaudited, in thousands, except share data)

           
      December 31,  December 31, 
         2020     2019 
    Assets      
    Current assets      
    Cash and cash equivalents $56,882  $50,412 
    Marketable securities - available-for-sale debt securities  311,335   39,130 
    Accounts receivable, net of allowance for doubtful accounts of $0 and $0  139    
    Other current assets and prepaid expenses (including current portion of clinical materials)  29,796   30,947 
    Total current assets   398,152    120,489 
           
    Restricted cash  4,602   4,496 
    Clinical materials     2,503 
    Operating lease right-of-use assets, net of accumulated amortization  18,880   20,789 
    Property, plant and equipment, net of accumulated depreciation  27,778   31,068 
    Intangibles, net of accumulated amortization  1,730   2,198 
    Total assets $ 451,142  $ 181,543 
           
    Liabilities and stockholders' equity      
    Current liabilities      
    Accounts payable $6,389  $6,357 
    Operating lease liabilities, current  2,773   2,493 
    Accrued expenses and other accrued liabilities  27,079   23,363 
    Deferred revenue, current  2,832   2,128 
    Total current liabilities   39,073    34,341 
           
    Operating lease liabilities, non-current  20,938   22,966 
    Deferred revenue, non-current  49,260    
    Other liabilities, non-current  644   598 
    Total liabilities   109,915    57,905 
           
    Stockholders' equity      
    Common stock - Ordinary shares par value £0.001, 1,038,249,630 authorized and 928,754,958 issued and outstanding (2019: 785,857,300 authorized and 631,003,568 issued and outstanding)  1,325   943 
    Additional paid in capital  935,706   585,623 
    Accumulated other comprehensive loss  (10,048)  (7,264)
    Accumulated deficit  (585,756)  (455,664)
    Total stockholders' equity   341,227    123,638 
           
    Total liabilities and stockholders' equity $ 451,142  $ 181,543 

    Consolidated Cash Flow Statement

    (unaudited, in thousands)

           
         Year ended  Year ended
      December 31,  December 31, 
         2020     2019 
    Cash flows from operating activities      
    Net loss $(130,092) $(137,165)
    Adjustments to reconcile net loss to net cash used in operating activities:      
    Depreciation  6,627   7,172 
    Amortization  967   838 
    Share-based compensation expense  10,414   11,053 
    Unrealized foreign exchange (gains) losses  (1,333)  1,076 
    Amortization (accretion) on available-for-sale debt securities  3,836   (185)
    Other  (55)  (13)
    Changes in operating assets and liabilities:      
    Decrease (increase) in receivables and other operating assets  1,747   (1,436)
    Decrease (increase) in non-current operating assets  2,458   (1,450)
    Increase (decrease) in payables and other liabilities  3,867   5,508 
    Increase (decrease) in deferred revenue  47,973   2,095 
    Net cash used in operating activities   (53,591)   (112,507)
           
    Cash flows from investing activities      
    Acquisition of property, plant and equipment  (2,341)  (1,592)
    Acquisition of intangibles  (565)  (1,482)
    Maturity or redemption of marketable securities  105,022   125,303 
    Investment in marketable securities  (381,040)  (27,284)
    Net cash (used in) provided by investing activities   (278,924)   94,945 
           
    Cash flows from financing activities      
    Proceeds from issuance of shares in the January offering  78,616    
    Proceeds from issuance of shares upon exercise of the overallotment for the January Offering  11,938                    — 
    Proceeds from issuance of shares in the June Offering  209,986    
    Proceeds from issuance of shares upon exercise of the overallotment for the June Offering  33,848    
    Proceeds from exercise of stock options  5,663   366 
    Net cash provided by financing activities   340,051    366 
           
    Effect of currency exchange rate changes on cash, cash equivalents and restricted cash  (960)  (372)
    Net increase (decrease) in cash, cash equivalents and restricted cash  6,576   (17,568)
    Cash, cash equivalents and restricted cash at start of period  54,908   72,476 
    Cash, cash equivalents and restricted cash at end of period $ 61,484  $ 54,908 

    Adaptimmune Contacts:

    Media Relations:

    Sébastien Desprez — VP, Communications and Investor Relations

    T: +44 1235 430 583

    M: +44 7718 453 176

    Investor Relations:

    Juli P. Miller, Ph.D. — Senior Director, Investor Relations

    T: +1 215 825 9310

    M: +1 215 460 8920


    1 All data updates subject to congress acceptance

    2 The main portion of the ADP-A2M4 Phase 1 trial is closed for enrollment

    3 Mortality figures based on American Cancer Society 2020 (US) and Global Can (EU) – synovial sarcoma data based on internal market research; MAGE-A4 expression ranges based on Adaptimmune samples and expression cut-off criteria of ≥30% tumor cells at ≥2+ intensity; HLA-A2 expression of 41% based on Adaptimmune samples (1,043 patient samples); serum AFP expression ranges based on internal samples (62 patients) and expression cut off >100ng/mL

    4 Pollack S, et al. Cancer Medicine. 2020; 9:4593–4602; Seto T, et al Med. Sci. 2019, 7, 48; van der Graaf WT, et al. 2012, Lancet, 379(9829), 1879-1886

    5 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.



    Primary Logo

    View Full Article Hide Full Article
  2. PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before the US markets open on Thursday, February 25, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day (details below).

    The press release and the live webcast of the conference call will be available in the investor section of Adaptimmune's corporate website at www.adaptimmune.com. An archive will be available after the call at that same address.

    To participate in the live conference…

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before the US markets open on Thursday, February 25, 2021. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) that same day (details below).

    The press release and the live webcast of the conference call will be available in the investor section of Adaptimmune's corporate website at www.adaptimmune.com. An archive will be available after the call at that same address.

    To participate in the live conference call, please dial (833) 652-5917 (U.S. or Canada) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (2099860).

    About Adaptimmune

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

    Adaptimmune Contacts:

    Media Relations:

    Sébastien Desprez — VP, Communications and Investor Relations

    T: +44 1235 430 583

    M: +44 7718 453 176

    Investor Relations:

    Juli P. Miller, Ph.D. — Senior Director, Investor Relations

    T: +1 215 825 9310

    M: +1 215 460 8920



    Primary Logo

    View Full Article Hide Full Article
  3. - SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

    - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers -

    - Efficacy with SPEAR T-cells in multiple solid tumor indications validates MAGE-A4 as a significant cancer target -

    - Plan for five new autologous products in the clinic including an HLA-independent TCR (HiT) and an enhanced tumor infiltrating lymphocyte (TIL) expressing IL-7 -

    - First two allogeneic products in the clinic by 2024 including a MAGE-A4 targeted product and a HiT targeting mesothelin partnered with Astellas -

    - Financial guidance updated: funded into early 2023 -

    - Virtual Investor Day today…

    - SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

    - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers -

    - Efficacy with SPEAR T-cells in multiple solid tumor indications validates MAGE-A4 as a significant cancer target -

    - Plan for five new autologous products in the clinic including an HLA-independent TCR (HiT) and an enhanced tumor infiltrating lymphocyte (TIL) expressing IL-7 -

    - First two allogeneic products in the clinic by 2024 including a MAGE-A4 targeted product and a HiT targeting mesothelin partnered with Astellas -

    - Financial guidance updated: funded into early 2023 -

    - Virtual Investor Day today from 8:00 a.m. to 10:30 a.m. EST (1:00 p.m. to 3:30 p.m. GMT) -

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day today, which will feature the Company's Senior Leadership team and Dr Dejka Araujo of the MD Anderson Cancer Center. The link to register is HERE and further background information on Adaptimmune and the event can be found HERE. After the event, a copy of the presentation materials and webcast links will be posted on the Events and Presentations page under the Investors section of the Adaptimmune website.

    "We will lay out the strategy confirming our leadership position as a company designing and delivering cell therapies for people with cancer," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "Over the next five years, we plan to deliver two marketed products, one in sarcoma and one in gastroesophageal cancers, and two additional BLAs in other solid tumor indications. We also plan to develop a robust autologous and allogeneic clinical pipeline that takes us towards the ultimate goal of curative and mainstream cell therapies for people with cancer."

    Adaptimmune's Virtual Investor Day will cover the following topics:

    Opening Remarks by Adrian Rawcliffe, CEO

    • Strategic vision for Adaptimmune and core value drivers for the next five years
    • Delivering TCR T-cell therapies and building the cell therapy company of the future ​
    • MAGE-A4 is a target with large market potential across a broad range of solid tumor indications including synovial sarcoma, lung, head and neck, bladder, and gastroesophageal cancers

    Synovial sarcoma care: the need for cell therapy

    • Dejka Araujo, M.D. (Professor in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center) will discuss the current treatment landscape and unmet medical need for people with synovial sarcoma

    Driving towards delivery of two marketed products and two further BLAs by 2025

    • An overview of plans to launch the first TCR T-cell therapy (ADP-A2M4) in synovial sarcoma as enrollment in the SPEARHEAD-1 trial is on track
    • Plan to file a BLA with ADP-A2M4D8 in gastroesophageal cancers in 2024
    • Potential addressable population across all tumor types with significant MAGE-A4 expression of ~39,000 patients per year in the US and EU factored for HLA-A21; additional BLA(s) projected with ADP-A2M4CD8 in tumor types beyond gastroesophageal cancers
    • Additional BLA projected for ADP-A2AFP (first or next-generation CD8α) with a potential market opportunity of ~16,000 patients per year based on serum AFP expression1 and factoring for HLA-A2
      • Plan to incorporate next-generation CD8α enhancement into SPEAR T-cells targeting AFP in a clinical trial next year 

    The importance of building an integrated cell therapy company for rapid execution and success

    • An overview of the Company's integrated structure with its leading capabilities for designing and delivering cell therapies
    • Case studies demonstrating the value that this integrated approach has delivered: rapid execution of clinical programs, security of vector supply, reduction of costs, and learnings applied to the allogeneic platform

    A rich cell therapy pipeline for the future over the next 5 years

    • Focusing on curative intent: leveraging translational insights for best next-generation products:
    • Positioning multiple enhancements for next-generation SPEAR T-cells including:
      • ADP-A2M4 SPEAR T-cells co-expressing IL-7, IL-15, dnTGFβ, and/ or PDE7
      • Enhancing SPEAR T-cells with IL-7 for proliferation and survival and CCL19 for migration into tumor in collaboration with Noile-Immune
      • Enhancing SPEAR T-cells using transmembrane and surface immunoregulatory mechanisms with Alpine Immune Sciences
    • Focusing on enabling mainstream access – broadening patient coverage and patient access:
      • Plans to expand into HLAs beyond A2 to increase the addressable patient population
      • Bringing forward HiT candidates for multiple targets including GPC3
      • Announcing collaboration with leading TIL therapy center (CCIT, Denmark) for nextgeneration TILs co-expressing IL-7
      • Bringing two allogeneic targets into the clinic:
        • In-house MAGE A4 targeted iPSC T-cell products
        • Mesothelin, a target expressed in multiple solid tumors, named as first HiT target in partnership with Astellas

    An update on the Company's financial position

    • Total liquidity position of $400 million as of September 30, 2020
    • Current cash runway into early 2023

    The Virtual Investor Day will also include two Q&A sessions.

    About Adaptimmune

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.  

    Media Relations:

    Sébastien Desprez — VP, Communications and Investor Relations

    T: +44 1235 430 583

    M: +44 7718 453 176

    Investor Relations:

    Juli P. Miller, Ph.D. — Senior Director, Investor Relations

    T: +1 215 825 9310

    M: +1 215 460 8920

    ________________

    1 Mortality figures based on American Cancer Society 2020 (US) and Global Can (EU) – Synovial sarcoma data based on internal market research; MAGE A4 expression ranges based on ADAP samples and expression cut-off criteria of ≥30% tumor cells at ≥2+ intensity; HLA-A2 expression of 41% based on ADAP samples (1,043 patient samples); Serum AFP expression ranges based on internal samples (62 patients) and expression cut off >100ng/mL 



    Primary Logo

    View Full Article Hide Full Article
  4. - Data support confidence in SPEARHEAD-1 as a registrational trial -

    - Projected to complete recruitment of all patients in Q1 2021 -

    - Median duration of response was 28 weeks with ongoing responses beyond 72 weeks in two patients; median overall survival has not been reached –

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, presented durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial at the virtual Connective Tissue Oncology Society (CTOS) annual meeting. The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand…

    - Data support confidence in SPEARHEAD-1 as a registrational trial -

    - Projected to complete recruitment of all patients in Q1 2021 -

    - Median duration of response was 28 weeks with ongoing responses beyond 72 weeks in two patients; median overall survival has not been reached –

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, presented durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial at the virtual Connective Tissue Oncology Society (CTOS) annual meeting. The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand for congress attendees. Dr. Van Tine will also participate in a "live stream" session entitled - Immunotherapy in Sarcoma: Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Synovial Sarcoma (Proffered Papers Panel Discussion) scheduled for 9 AM EST today (November 19).

    "The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment. This leads to the highest quality of life I have been able to provide patients with synovial sarcoma after treatment," said Dr. Brian Van Tine, Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine.

    "Data from this trial have enabled rapid execution of our pivotal trial, SPEARHEAD-1, and support our aim to commercialize ADP-A2M4 as the first engineered TCR T-cell product in the US in 2022," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "However, this is only the beginning of the tremendous potential of our products targeting MAGEA4. We will rapidly pursue additional indications, starting with the Phase 2 trial in gastroesophageal cancers with ADP-A2M4CD8 expected to initiate in the first half of 2021."

    Data presented at CTOS were updated durability of response and safety data from the 16 patients with synovial sarcoma who were treated in the Phase 1 ADP-A2M4 trial, presented earlier this year at ASCO. The data cut-off for this presentation was September 1, 2020 and results are summarized below:

    • Seven out of 16 patients (44%) had confirmed partial responses (PRs) per RECIST criteria, with disease control in 15 patients (94%)
    • There was a median duration of response of 28 weeks (range: 12-72+ weeks) with two PRs that were ongoing beyond 72 weeks at the time of data cut-off
    • Eleven out of 16 patients were alive at data cut-off and median overall survival had not been reached
    • Translational data indicate that induction of the IFNγ-related pathway by serum analyses is an emerging biomarker of response. MAGE-A4 expression and transduced cell dose correlate with tumor reduction
    • Most adverse events were consistent with those typically experienced by cancer patients undergoing lymphodepletion chemotherapy and cellular therapy including low blood counts and cytokine release syndrome

    About Adaptimmune

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

    Media Relations:

    Sébastien Desprez — VP, Communications and Investor Relations

    T: +44 1235 430 583

    M: +44 7718 453 176

    Investor Relations:

    Juli P. Miller, Ph.D. — Senior Director, Investor Relations

    T: +1 215 825 9310

    M: +1 215 460 8920



    Primary Logo

    View Full Article Hide Full Article
  5. PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and further details are on the Investor Relations tab of the Adaptimmune website.

    The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by Adaptimmune's Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer…

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A link to register is available HERE and further details are on the Investor Relations tab of the Adaptimmune website.

    The Company plans to showcase the market potential for its SPEAR T-cell portfolio as well as provide details about its early stage pipeline with multiple cell therapies beyond its current autologous TCR T-cell products. Presentations will be given by Adaptimmune's Senior Leadership Team in addition to Dr. Dejka Araujo from the Department of Sarcoma Medical Oncology, Division of Cancer Medicine of the MD Anderson Cancer Center.

    About Adaptimmune 

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. 

    Forward-Looking Statements 

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the SEC on November 5, 2020, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. 

    Media Relations:

    Sébastien Desprez — VP, Communications and Investor Relations

    T: +44 1235 430 583

    M: +44 7718 453 176

    Investor Relations:

    Juli P. Miller, Ph.D. — Senior Director, Investor Relations

    T: +1 215 825 9310

    M: +1 215 460 8920

    Primary Logo

    View Full Article Hide Full Article
View All Adaptimmune Therapeutics plc News